Evidence map›Paper›PMID 38507118›Full record

ReviewHuman cell2024

CLLU1 as an emerging biomarker in chronic lymphoid leukemia.

Chunmeng Rong, Chenhao Liang, Jinze Shen, Yuhua Zhang, Qurui Wang, Fang Yang, Yalu Chen, Yuqing Luo, Meier Gu, Panpan Gao and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Human cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Chunmeng Rong *Department of Hematology, Yuyao People's Hospital of Zhejiang Province, Ningbo, Zhejiang, China.
Chenhao Liang *Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China.
Jinze ShenKey Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China.
Yuhua ZhangKey Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China.
Qurui WangKey Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China.
Fang YangDepartment of Hematology, Yuyao People's Hospital of Zhejiang Province, Ningbo, Zhejiang, China.
Yalu ChenDepartment of Hematology, Yuyao People's Hospital of Zhejiang Province, Ningbo, Zhejiang, China.
Yuqing LuoDepartment of Hematology, Yuyao People's Hospital of Zhejiang Province, Ningbo, Zhejiang, China.
Meier GuDepartment of Hematology, Yuyao People's Hospital of Zhejiang Province, Ningbo, Zhejiang, China.
Panpan GaoDepartment of Hematology, Yuyao People's Hospital of Zhejiang Province, Ningbo, Zhejiang, China.
Yongming XiaDepartment of Hematology, Yuyao People's Hospital of Zhejiang Province, Ningbo, Zhejiang, China. yy_xyzlnk@163.com.
Shiwei DuanKey Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, Zhejiang, China. duansw@hzcu.edu.cn.ORCID http://orcid.org/0000-0001-7682-2877
Yuxian People's Hospital · CNHangzhou City UniversityCommunication University of Zhejiang · CN

Funding

the Natural Science Foundation project of Ningbo Science and Technology Bureau 2022J040
6 · The paper itself

Abstract

CLLU1, a disease-specific gene associated with chronic lymphoid leukemia (CLL), is located on chromosome 12q22. Previous studies considered CLLU1 to be a non-coding RNA; however, recent research has discovered that its coding sequence region possesses the potential to encode a short peptide similar to interleukin-4. Remarkably, abnormally elevated expression of CLLU1 has only been detected in chronic lymphoid leukemia among all hematological cancers. High CLLU1 expression often indicates more malignant pathological features and an unfavorable prognosis for patients. Importantly, the expression level of CLLU1 remains unaffected by the passage of time or therapeutic interventions, thus rendering it a novel prognostic marker. This article provides a comprehensive summary of relevant research findings on CLLU1 in the context of CLL prognosis and clinical applications, aiming to guide subsequent theoretical and clinical investigations in this field.

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellRNA, Long NoncodingBiomarkers, TumorGenes, NeoplasmHumansNeoplasm ProteinsBiomarkers, TumorNeoplasm ProteinsRNA, Long NoncodingBiomarkerChronic lymphoid leukemiaCLLU1Non-coding RNAPrognosis

Identifiers

PMID38507118
OpenAlexW4393010265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.